University of Birmingham
The University of Birmingham, established in 1900, is a prominent educational institution in the United Kingdom, dedicated to advancing knowledge through undergraduate and postgraduate programs in various fields, including life sciences, arts, law, and technology. With a long-standing tradition of innovation, the University engages in groundbreaking research that addresses contemporary challenges and contributes to societal well-being. The Birmingham Centre for Energy Storage (BCES) exemplifies this commitment by harnessing research expertise to facilitate the transition of energy storage technologies from the laboratory to practical applications, emphasizing the importance of integrated energy systems. Additionally, the University manages an endowment fund that supports scholarships, research initiatives, and academic programs, further solidifying its role as a leader in education and research on the international stage.
Chromatwist they provide shifted organic fluorescent dyes which, when irradiated with UV light, become visible blue excitation sources. Their patented innovative molecular technology platform coupled to their modular and scalable chemistry allows the development of their fluorophores to further push the boundaries of applications in the healthcare sector through their use in bio-sensing (e.g. flow cytometry) and bio-imaging (e.g. multiphoton microscopy).
Linear Diagnostics Limited (LDL) is a diagnostics company based on a novel technology that allows wide range of molecular diagnostics tests to be carried out using a simple optical system. The technology provides significant advantages over the current state of the art allowing a more rapid detection of multiple targets using a single simple reagent
Tyseley Energy Park develops an Energy Innovation Zone (EIZ) to help Tyseley and Birmingham overcome the severe energy business and social challenges it currently faces. The TEP EIZ reduces emissions and stimulates growth and will integrate low carbon technologies and infrastructure needed to support new approaches to clean energy.
Cytox have developed a simple genetic based blood test for the assessment of risk and diagnosis of Alzheimer's Disease in the very early stages. Alzheimer's Disease affects over 26 million people world-wide and is a growing condition as people live longer. There is currently no cure for Alzheimer's Disease, but there are large international initiatives underway to find treatments with many drugs in clinical development. Cytox are commercially launching their tests in conjunction with Affymetrix (part of Thermo Fisher Scientific) to support Pharmaceutical and Biotechnology companies developing novel therapeutics.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.